Compare DGII & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DGII | NVAX |
|---|---|---|
| Founded | 1985 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1995 | 1996 |
| Metric | DGII | NVAX |
|---|---|---|
| Price | $47.23 | $8.49 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 9 |
| Target Price | ★ $48.80 | $11.33 |
| AVG Volume (30 Days) | 228.0K | ★ 3.7M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 77.05 | ★ 309.76 |
| EPS | 0.31 | ★ 2.58 |
| Revenue | $430,221,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $18.71 | N/A |
| Revenue Next Year | $7.22 | N/A |
| P/E Ratio | $153.15 | ★ $3.28 |
| Revenue Growth | 1.46 | ★ 64.69 |
| 52 Week Low | $22.39 | $5.01 |
| 52 Week High | $51.78 | $11.85 |
| Indicator | DGII | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 44.03 | 38.12 |
| Support Level | $42.69 | $8.01 |
| Resistance Level | $47.86 | $9.05 |
| Average True Range (ATR) | 1.71 | 0.54 |
| MACD | -0.35 | -0.23 |
| Stochastic Oscillator | 5.53 | 1.81 |
Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.